Literature DB >> 23229050

Putative role of the mTOR/4E-BP1 signaling pathway in the carcinogenesis and progression of gastric cardiac adenocarcinoma.

Hai Yan Yang1, Li Ying Xue, Ling Xiao Xing, Juan Wang, Jun Ling Wang, Xia Yan, Xiang Hong Zhang.   

Abstract

The mammalian target of rapamycin/eukaryotic translation inititiation factor 4E binding protein 1 (mTOR/4E-BP1) transduction pathway is activated in a range of malignant cancers, but its role in human gastric cardiac adenocarcinoma (GCA) has not been well defined. The present study used western blotting and reverse transcription polymerase chain reaction (RT-PCR) to assess the expression of mTOR, 4E-BP1 and eukaryotic translation initiation factor 4E (eIF4E) at the protein and mRNA levels in 33 cases of GCA and paired adjacent normal gastric mucosal tissues. The expression of mTOR at the protein level in GCA was significantly lower than that in the corresponding normal gastric mucosa (0.296 ± 0.27 vs. 1.348 ± 0.80, P<0.05), but the ratio of p-mTOR to mTOR was significantly increased in tumor tissues (1.425 ± 1.07 vs. 0.450 ± 0.24, P<0.05). The expression of 4E-BP1 was significantly decreased in GCA compared with normal tissues (p<0.05), while the levels of phosphorylated 4E-BP1 (p-4E-BP1) were markedly increased in tumor tissues (p<0.05). The levels of phosphorylated eIF4E (p‑eIF4E) were significantly higher in the tumors in comparison to the corresponding normal tissues (1.822 ± 0.63 vs. 0.997 ± 0.38, P<0.05), and the levels of p-eIF4E were closely correlated with lymph node metastasis (p<0.05). The mTOR/4E-BP1 signaling pathway is activated in GCA, with mTOR activated mainly through increased mTOR phosphorylation rather than protein overexpression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23229050     DOI: 10.3892/mmr.2012.1208

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

1.  The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.

Authors:  Oscar Tapia; Ismael Riquelme; Pamela Leal; Alejandra Sandoval; Susana Aedo; Helga Weber; Pablo Letelier; Enrique Bellolio; Miguel Villaseca; Patricia Garcia; Juan Carlos Roa
Journal:  Virchows Arch       Date:  2014-05-21       Impact factor: 4.064

2.  The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines.

Authors:  Ismael Riquelme; Oscar Tapia; Jaime A Espinoza; Pamela Leal; Kurt Buchegger; Alejandra Sandoval; Carolina Bizama; Juan Carlos Araya; Richard M Peek; Juan Carlos Roa
Journal:  Pathol Oncol Res       Date:  2016-05-07       Impact factor: 3.201

3.  Integrin β6 can be translationally regulated by eukaryotic initiation factor 4E: Contributing to colonic tumor malignancy.

Authors:  Liu Enyu; Niu Zhengchuan; Wang Jiayong; Liang Benjia; Sun Qi; Qin Ruixi; Peng Cheng; Abdul Qadir Khan; Song Wei; Niu Jun
Journal:  Tumour Biol       Date:  2015-05-17

4.  Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer.

Authors:  Guo-Dong Cao; Xing-Yu Xu; Jia-Wei Zhang; Bo Chen; Mao-Ming Xiong
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

5.  Tumor-biopsy stratification based on mTOR-pathway activity and functional mutations in the upstream genes PIK3CA and PTEN.

Authors:  Jean-François Laes; Sebastien Sauvage; Gregori Ghitti
Journal:  Oncotarget       Date:  2017-09-28

6.  Pharmacogenomic Testing to Guide Personalized Cancer Medicine Decisions in Private Oncology Practice: A Case Study.

Authors:  George Astras; Christos I Papagiannopoulos; Konstantinos A Kyritsis; Constantina Markitani; Ioannis S Vizirianakis
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.